Nuveen’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Nuveen’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-45,568	Closed	-$6M	–	3426
2020 Q4	$6M	Buy	45,568 +1,556	+4%	+$138K	﹤0.01%	1974
2020 Q3	$2.22M	Sell	44,012 -5,387	-11%	-$242K	﹤0.01%	2329
2020 Q2	$2.35M	Sell	49,399 -8,218	-14%	-$382K	﹤0.01%	2270
2020 Q1	$2.82M	Buy	57,617 +2,524	+5%	+$129K	﹤0.01%	2024
2019 Q4	$3.16M	Sell	55,093 -2,593	-4%	-$128K	﹤0.01%	2228
2019 Q3	$2.08M	Buy	57,686 +16,280	+39%	+$636K	﹤0.01%	2379
2019 Q2	$1.29M	Buy	+41,406	New	+$1.12M	﹤0.01%	2636

Nuveen's EIDX Position: Q1 2021 in Review

Nuveen sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 45,568 shares — an estimated $6M sold.

Nuveen first reported a position in EIDX in Q2 2019 and held it in 7 quarters. The position peaked at $6M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Nuveen reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Nuveen sold 45,568 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $6M.
Nuveen first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2019 and held it in 7 quarters.
Nuveen's Eidos Therapeutics, Inc. Common Stock position peaked at $6M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Nuveen's 13F filing for Q1 2021, filed 17 May 2021.